Who is sponsoring NCT02231138?

NCT02231138 is sponsored by Chinese PLA General Hospital.

What drugs are being tested in NCT02231138?

Interventions in NCT02231138: Abelmoschus manihot (AM).

What condition does NCT02231138 study?

NCT02231138 studies Chronic Kidney Disease.

Is NCT02231138 still recruiting?

NCT02231138 is currently status unknown. Last updated 31 May 2016.

Last reviewed 2016-05-31 · How we verify

NCT02231138

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease：a Multicentre Open Study

Status unknown Phase 4 Last updated 31 May 2016

What this trial tests

Phase 4 trial testing Abelmoschus manihot (AM) in Chronic Kidney Disease in 1,600 participants. Status unknown.

Timeline

1 September 2014

Primary endpoint
1 January 2016

1 December 2016

Quick facts

Lead sponsor	Chinese PLA General Hospital
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	1,600
Start date	1 September 2014
Primary completion	1 January 2016
Estimated completion	1 December 2016
Sites	78 locations across China

Drugs / interventions tested

Abelmoschus manihot (AM) — full drug profile →

Conditions studied

Chronic Kidney Disease — all drugs for Chronic Kidney Disease →

Sponsor

Chinese PLA General Hospital

Who can join

Eligibility, any sex, with Chronic Kidney Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change in 24-h proteinuria from baseline after treatment
Time frame: Baseline(week 0), week 12, week 24

Sponsor's own description

Huangkui Capsule is a single medicament of traditional Chinese medicine consists of Abelmoschus manihot and has been widely used to treat kidney disease. The purpose of this study is to evaluate the safety and efficacy of Abelmoschus manihot for treating chronic kidney disease in large scale samples with long time take.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Chronic Kidney Disease

Currently open trials in the same condition.

NCT07469540 — Effects of an Aerobic Exercise Program on Cardiovascular Risk in Patients With Chronic Kidney Disease or Rheumatoid Arth · NA · recruiting
NCT07169422 — Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care · NA · recruiting
NCT07481526 — A Prospecitve Multicenter, Observational Registry Study · recruiting
NCT07450820 — OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD · recruiting
NCT07107945 — A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease · Phase 3 · recruiting

Other Chinese PLA General Hospital trials

Trials by the same sponsor.

NCT07294755 — The Impact of Intrapleural Block on Postoperative Pain Caused by Drainage Tubes After Thoracoscopic Surgery · NA · not yet recruiting
NCT07536607 — Predictive Role of Photon Counting Computed Tomography in Acute Coronary Syndrom Patients · not yet recruiting
NCT07489157 — Real-Time End-Tidal Carbon Dioxide Monitoring for Early Warning of Hypoxemia in Painless Gastrointestinal Endoscopy · NA · not yet recruiting
NCT07494981 — Individualized Precision Therapy With Ceftazidime and Avibactam Guided by PK/PD in Geriatric Populations · not yet recruiting
NCT07496008 — Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02231138 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese PLA General Hospital
Last refreshed: 31 May 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02231138.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing